文献速递系统性红斑狼疮

美金刚治疗改善系统性红斑狼疮患者神经心理功能:2期随机安慰剂对照临床试验

Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial.
PubMed 文献 · Ann Rheum Dis · 2026-08-22

ClearMEMory试验纳入56例伴客观神经心理功能障碍的SLE成人患者,随机接受美金刚滴定至40 mg/d或安慰剂治疗12周。

要点

  • 美金刚12周治疗可改善SLE患者客观神经心理功能,RBANS总分改善优于安慰剂。
  • RBANS总分增加≥8的临床重要改善率美金刚组66.7%,安慰剂组36.0%,NNT=3.3。

核心结论

  • 在伴神经心理功能障碍的SLE患者中,美金刚治疗12周改善了客观神经心理功能。

研究设计与样本

  • ClearMEMory(NCT03527472)为多中心、随机、安慰剂对照12周临床试验,美金刚滴定至40 mg/d。
  • 筛查131例,随机56例,完成主要结局评估并分析43例(美金刚组18例,安慰剂组25例)。

主要发现

  • 因不良事件停药者美金刚组5例(19%),安慰剂组5例(17%)。

关键数值与推荐

  • 主要结局为RBANS总分从基线至第12周的变化。
  • 临床重要改善阈值定义为RBANS总分增加≥8。

临床怎么用

  • 对于伴客观神经心理功能障碍的SLE患者,可考虑美金刚治疗以改善客观神经心理功能。

局限性

  • 完成主要结局评估并分析的样本量较小(美金刚组18例,安慰剂组25例)。
  • 患者总体印象改善组间差异未达统计学意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Neuropsychological symptoms are common, disabling manifestations of systemic lupus erythematosus (SLE) that can persist despite immunomodulatory treatment. We evaluated whether the N-methyl-D-aspartate receptor (NMDAR) antagonist, memantine, improves cognitive function in individuals with SLE and neuropsychological dysfunction. METHODS: ClearMEMory (NCT03527472) was a multisite, randomised, placebo-controlled 12-week clinical trial of memantine titrated to 40 mg/d among adults with SLE with objective neuropsychological dysfunction. The primary outcome was change in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total score from baseline to week 12. Additional outcomes included change in RBANS total score above a threshold considered clinically important (score increase ≥8) and patient global impression of change (PGI-C). RESULTS: Of 131 patients screened, 56 were randomised, and 43 completed primary outcome assessment and were analysed, including 18 in the memantine group and 25 in the placebo group. Improvement in RBANS total score between baseline and week 12 was greater in the memantine group (median change: +8) than the placebo group (median change: +5) (P = .032); 12 (66.7%) participants in the memantine group and 9 (36.0%) participants in the placebo group had an increase in total RBANS score ≥8 (P = .047) (number-needed-to-treat = 3.3). Using the PGI-C, 61% of participants in the memantine group and 36% of participants in the placebo group self-reported improvement (P = .19). Discontinuation due to adverse events occurred in 5 (19%) participants in the memantine group and 5 (17%) participants in the placebo group. CONCLUSIONS: Among patients with SLE-associated neuropsychological dysfunction, treatment with memantine for 12 weeks improved objective neuropsychological function.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Rhoads JP, Ahmad LN, Williams J, et al. Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial. Ann Rheum Dis. 2026. PMID: 42629232. doi:10.1016/j.ard.2026.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。